CN112888674B - 多环化合物作为可溶性环氧化物水解酶抑制剂 - Google Patents
多环化合物作为可溶性环氧化物水解酶抑制剂 Download PDFInfo
- Publication number
- CN112888674B CN112888674B CN201980048385.XA CN201980048385A CN112888674B CN 112888674 B CN112888674 B CN 112888674B CN 201980048385 A CN201980048385 A CN 201980048385A CN 112888674 B CN112888674 B CN 112888674B
- Authority
- CN
- China
- Prior art keywords
- group
- hexahydro
- methyl
- urea
- acetylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/14—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382445.7 | 2018-06-20 | ||
| EP18382445.7A EP3584236A1 (en) | 2018-06-20 | 2018-06-20 | Polycyclic compounds soluble epoxide hydrolase inhibitors |
| PCT/EP2019/066181 WO2019243414A1 (en) | 2018-06-20 | 2019-06-19 | Polycyclic compounds as soluble epoxide hydrolase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112888674A CN112888674A (zh) | 2021-06-01 |
| CN112888674B true CN112888674B (zh) | 2023-06-30 |
Family
ID=62784072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980048385.XA Active CN112888674B (zh) | 2018-06-20 | 2019-06-19 | 多环化合物作为可溶性环氧化物水解酶抑制剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210261564A1 (enExample) |
| EP (2) | EP3584236A1 (enExample) |
| JP (1) | JP7442828B2 (enExample) |
| KR (1) | KR102806466B1 (enExample) |
| CN (1) | CN112888674B (enExample) |
| AU (1) | AU2019291034B2 (enExample) |
| BR (1) | BR112020026027A2 (enExample) |
| CA (1) | CA3104342A1 (enExample) |
| EA (1) | EA202190072A1 (enExample) |
| ES (1) | ES2975451T3 (enExample) |
| IL (1) | IL279496A (enExample) |
| MX (1) | MX2020014276A (enExample) |
| WO (1) | WO2019243414A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113831301B (zh) * | 2020-06-08 | 2023-06-06 | 沈阳药科大学 | 苯并噻唑类衍生物及其用途 |
| EP4063348A1 (en) | 2021-03-24 | 2022-09-28 | Universitat de Barcelona | Compounds as soluble epoxide hydrolase inhibitors |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2261637A1 (de) * | 1972-12-16 | 1974-06-20 | Basf Ag | 5,8 : 7.10-dimethano-5.6.7.8.9.10-hexa-hydro-benzo-cyclooctene und verfahren zu ihrer herstellung |
| CN101679258A (zh) * | 2007-03-13 | 2010-03-24 | 亚瑞特医疗公司 | 作为可溶性环氧化合物水解酶抑制剂的4-哌啶基脲化合物 |
| CN104093708A (zh) * | 2012-02-01 | 2014-10-08 | 加利福尼亚大学董事会 | 可溶性环氧化物水解酶的酰基哌啶抑制剂 |
| AU2016301027A1 (en) * | 2015-07-28 | 2018-03-08 | Universitat De Barcelona | Analogs of adamantylureas as soluble epoxide hydrolase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2210799A1 (de) | 1972-03-07 | 1973-09-20 | Basf Ag | 5,9:7,11-dimethano-8-hetero-11h-5,6. 7.8.9.10-hexahydro-benzo-cyclononene |
| WO2000023060A2 (en) | 1998-10-20 | 2000-04-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method of treating immunological disorders mediated by t-lymphocytes |
| DE60222264T2 (de) | 2001-06-29 | 2008-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Phenylpyrazolderivate als seh-inhibitoren |
| WO2007009001A1 (en) | 2005-07-12 | 2007-01-18 | The Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders |
| US7851474B2 (en) | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
| WO2017120012A1 (en) | 2016-01-05 | 2017-07-13 | The Regents Of The University Of California | Methods of treating mental disorders |
-
2018
- 2018-06-20 EP EP18382445.7A patent/EP3584236A1/en not_active Withdrawn
-
2019
- 2019-06-19 AU AU2019291034A patent/AU2019291034B2/en active Active
- 2019-06-19 EA EA202190072A patent/EA202190072A1/ru unknown
- 2019-06-19 BR BR112020026027-4A patent/BR112020026027A2/pt not_active Application Discontinuation
- 2019-06-19 CN CN201980048385.XA patent/CN112888674B/zh active Active
- 2019-06-19 CA CA3104342A patent/CA3104342A1/en active Pending
- 2019-06-19 ES ES19731287T patent/ES2975451T3/es active Active
- 2019-06-19 KR KR1020217001663A patent/KR102806466B1/ko active Active
- 2019-06-19 JP JP2020570515A patent/JP7442828B2/ja active Active
- 2019-06-19 WO PCT/EP2019/066181 patent/WO2019243414A1/en not_active Ceased
- 2019-06-19 US US17/253,041 patent/US20210261564A1/en not_active Abandoned
- 2019-06-19 MX MX2020014276A patent/MX2020014276A/es unknown
- 2019-06-19 EP EP19731287.9A patent/EP3810572B1/en active Active
-
2020
- 2020-12-16 IL IL279496A patent/IL279496A/en unknown
-
2024
- 2024-08-08 US US18/798,430 patent/US20240400575A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2261637A1 (de) * | 1972-12-16 | 1974-06-20 | Basf Ag | 5,8 : 7.10-dimethano-5.6.7.8.9.10-hexa-hydro-benzo-cyclooctene und verfahren zu ihrer herstellung |
| CN101679258A (zh) * | 2007-03-13 | 2010-03-24 | 亚瑞特医疗公司 | 作为可溶性环氧化合物水解酶抑制剂的4-哌啶基脲化合物 |
| CN104093708A (zh) * | 2012-02-01 | 2014-10-08 | 加利福尼亚大学董事会 | 可溶性环氧化物水解酶的酰基哌啶抑制剂 |
| AU2016301027A1 (en) * | 2015-07-28 | 2018-03-08 | Universitat De Barcelona | Analogs of adamantylureas as soluble epoxide hydrolase inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications;Hong C. Shen et al;《J. Med. Chem.》;20121231;第55卷;1789-1808 * |
| Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors;Sung Hee Hwang et al;《J. Med. Chem.》;20071231;第50卷;3825-3840 * |
| Searching for novel applications of the benzohomoadamantane scaffold in medicinal chemistry: Synthesis of novel 11b-HSD1 inhibitors;Elena Valverde et al;《Bioorg. Med. Chem.》;20151231;第23卷;7601-7617 * |
| Soluble epoxide hydrolase inhibitors:a patent review;Hong C.Shen et al;《Expert Opin.Ther.Patents》;20101231;第20卷;941-956 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3104342A1 (en) | 2019-12-26 |
| BR112020026027A2 (pt) | 2021-03-23 |
| EP3584236A1 (en) | 2019-12-25 |
| JP2021535895A (ja) | 2021-12-23 |
| KR20210024027A (ko) | 2021-03-04 |
| AU2019291034A1 (en) | 2021-01-14 |
| IL279496A (en) | 2021-01-31 |
| EA202190072A1 (ru) | 2021-10-15 |
| EP3810572C0 (en) | 2023-11-15 |
| ES2975451T3 (es) | 2024-07-05 |
| EP3810572A1 (en) | 2021-04-28 |
| MX2020014276A (es) | 2021-05-28 |
| AU2019291034B2 (en) | 2024-01-04 |
| CN112888674A (zh) | 2021-06-01 |
| WO2019243414A1 (en) | 2019-12-26 |
| US20240400575A1 (en) | 2024-12-05 |
| KR102806466B1 (ko) | 2025-05-13 |
| EP3810572B1 (en) | 2023-11-15 |
| JP7442828B2 (ja) | 2024-03-05 |
| US20210261564A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2647851C2 (ru) | Способы получения некоторых 2-(пиридин-3-ил)тиазолов | |
| AU665007B2 (en) | New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| JP4853965B2 (ja) | アダマンタン誘導体およびアザビシクロオクタン誘導体およびアザビシクロノナン誘導体、ならびにこれらの調製方法およびdpp−iv阻害剤としてのこれらの使用 | |
| CN107108581B (zh) | 作为强效rock抑制剂的回接苯甲酰胺衍生物 | |
| US9981918B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP2739615B1 (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| KR20070032787A (ko) | 염증 질환 치료용 히단토인 유도체 | |
| US10065964B2 (en) | Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors | |
| CN105358547A (zh) | 作为强效rock1和rock2抑制剂的苯基吡唑衍生物 | |
| JP2011510993A (ja) | β−セクレターゼ(BACE)阻害剤として有用な2−アミノ−キノリン誘導体 | |
| KR20080080195A (ko) | 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도 | |
| WO2022194066A1 (zh) | Kras g12d抑制剂及其在医药上的应用 | |
| US20240400575A1 (en) | Polycyclic compounds as soluble epoxide hydrolase inhibitors | |
| TW201702226A (zh) | 尿素衍生物或其醫藥上可接受鹽 | |
| EA008801B1 (ru) | Получение арилалкилкарбаматных производных и их применение в терапии | |
| CA3106354A1 (en) | Amino-pyridinyl-azetidinyl-carboxamide derivatives and pharmaceutical compositions thereof useful as inhibitors of histone deacetylase | |
| WO2010004198A2 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
| CN119039379B (zh) | 一种蛋白降解靶向嵌合体分子及其应用 | |
| CN105008341B (zh) | 取代的色满‑6‑基氧基‑环烷烃及其作为药物的用途 | |
| HK40052677A (en) | Polycyclic compounds as soluble epoxide hydrolase inhibitors | |
| CN101415711A (zh) | 用于治疗香草素受体1相关病症的新的螺[咪唑烷-4,3’-吲哚]2,2’’,5’(1h)-三酮 | |
| CN116547277A (zh) | P300抑制剂及其在医药上的应用 | |
| AU2008201593A1 (en) | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
| NZ621357B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40052677 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |